Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Research discovery may lead to advances in heart disease and cancer treatment

15.04.2010
Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer. The study is published in the April 16th issue of the Journal of Biological Chemistry.

The antibiotic, rapamycin, is used on drug-eluting stents implanted during angioplasty because it is effective in preventing restenosis (re-narrowing or reclosure) of arteries. However, rapamycin can also prevent tissue from growing over and covering the metal stents, a critical part of the artery's healing after angioplasty. Without this protective covering, blood clots can develop many months later, called late stent thrombosis. These clots can lead to a heart attack.

"Late stent thrombosis has emerged as a major factor diminishing the benefits of drug-eluting stents, highlighting the need for a better understanding of the antimigratory mechanism of rapamycin and its analogs," notes Dr. Woods.

Through a series of experiments, the researchers found that by silencing a protein made by cells exposed to mTOR inhibitors, a class of drugs including rapamycin, they could block rapamycin's inhibitory effect on cell migration.

"We identified specific changes in proteins that a class of drugs, called mTOR inhibitors, uses to block cell movement," said Dr. Woods. "This knowledge will help us to better design strategies to help arteries heal following angioplasty or to prevent tumor growth."

Studies like this one often have application beyond the original research question because they identify basic mechanisms involved in many biologic processes. Cell migration in cancer is not only important in tumor growth, but also in the spread of cancer to other sites in the body.

Heart disease is the leading cause of death in the United States. Coronary heart disease is the most common type of heart disease. According to the American Heart Association, in 2006, an estimated 1.3 million angioplasty procedures were performed. It has been estimated that about 60% of angioplasty procedures performed now are performed with drug-eluting stents.

Cancer is the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths.

The research team also included Stephanie Moss and Daniel Lightell, Jr. at Ochsner Clinic Foundation, and Steven O. Marx, MD, and Andrew R. Marks, MD from Columbia University College of Physicians and Surgeons..

This research was funded by a COBRE grant from the National Institutes of Health's National Center for Research Resources to LSU Health Sciences Center New Orleans Department of Pharmacology and grants from the Greater Southeast Affiliate of the American Heart Association to Ochsner Clinic Foundation.

LSU Health Sciences Center New Orleans educates Louisiana's health care professionals. The state's academic health leader, LSUHSC comprises a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSUHSC faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSUHSC research enterprise generates jobs and enormous economic impact, LSUHSC faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit http://www.lsuhsc.edu and http://www.twitter.com/LSUHSCHealth.

Leslie Capo | EurekAlert!
Further information:
http://www.lsuhsc.edu

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>